tldrdailynews.com logo

Chinese Biotech's New GLP-1 Drug Shows Promise in Weight Loss Trials

1 min read
Source: Bloomberg.com
Chinese Biotech's New GLP-1 Drug Shows Promise in Weight Loss Trials
Photo: Bloomberg.com
TL;DR

Hangzhou Sciwind Biosciences has developed ecnoglutide, a promising obesity drug that showed over 15% weight loss in late-stage trials, positioning it as a competitor to Eli Lilly's Zepbound and Novo Nordisk's Wegovy, with potential approval in China by 2026 and plans for international development.

Topics:businesshealth#biotech#china#ecnoglutide#health#obesity#weightloss
Share this article
  1. Chinese Biotech Showcases Challenger to Eli Lilly’s Obesity Drug  Bloomberg.com
  2. China's Sciwind's GLP-1 shows similar weight loss to Novo's Wegovy, study finds  Reuters
  3. New weight-loss drug sails through all-important Phase III trial  New Atlas
  4. Novel GLP-1 Agonist Promotes Safe and Effective Weight Loss  Medscape
  5. China, where obesity levels are low, becomes hotbed for weight loss drug trials  STAT

Want the full story? Read the original reporting

Read on Bloomberg.com